Stocks expected to have increasing option volume: SRPT CCL SATS X
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI
June 17, 2025 4:02 PM EDTEvercore ISI analyst Gavin Clark-Gartner lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 (from $50.00) while maintaining a In Line rating.
The analyst comments "Following the second recent Elevidys-related death due to liver failure, were reiterating our In-Line rating and lowering our PT to $28/sh. See our previous downgrade note for more details on the broader setup. Some thoughts on the path forward: Tough to... More
Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral
June 17, 2025 7:14 AM EDTGoldman Sachs analyst Salveen Richter downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Neutral with a price target of $29.00.
The analyst comments "We downgrade SRPT to Neutral from Buy as we see an uncertain outlook amidst safety concerns, following the second reported death of a non-ambulatory Elevidys-treated Duchenne muscular dystrophy patient due to acute liver failure (ALF). SRPT plans to convene a Duchenne and liver health expert panel to consider enhanced immunosuppression, as the company believes that adding... More
Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
June 16, 2025 2:47 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight with a price target of $40.00 (from $113.00).
The analyst comments "Second patient death raises concerns as use in non-ambulatory patients restricted (commercial and clinical), while enhanced immunosuppressive regimen in development... More
BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
June 16, 2025 11:07 AM EDTBMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $70.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Management is taking all the right/necessary measures to understand the recent non-ambulatory patient deaths and prevent future ambulatory/non-ambulatory deaths. Given the significant... More
